Eqalis Cbd30
Eqalis CBD30 Recall Summary Eqalis Pharmaceuticals Limited is recalling Eqalis CBD30, an oral solution containing 30 mg/mL of CBD, which was distributed to hospitals, pharmacies, and laboratories in New Zealand. The product has been classified as a Class I recall, indicating a serious issue with the medication. The specific reason for the recall has not been detailed in this notice.
- Recalling firm
- Eqalis Pharmaceuticals Limited
- Product
- Eqalis CBD30. [Medicine]. Form: Oral solution 30 mg/mL
- Reason
- Dithiocarbamates (CS2) were detected in two batches of Eqalis-manufactured full-spectrum dosage products, exceeding the OOS limit of <2 mg/kg.
- Classification
- Class I
- Category
- drug recall
- Country
- New Zealand
- Agency
- MEDSAFE
- Recall date
- 2026-05-28
- Status
- Ongoing
- Distribution
- New Zealand - Hospital/Pharmacy/Laboratory
Official recall notice from MEDSAFE
Recall details on Nibble Recalls: https://trynibble.app/recalls/3a4d994d-7c35-4673-880d-81cfe1d68168